About Examworks Group (NYSE:EXAM)
ExamWorks Group, Inc. is a provider of independent medical examinations (IMEs), peer reviews, bill reviews, Medicare compliance, case management and other related services (IME services or the IME industry). The Company conducts its business through four geographic segments, namely, the United States, Canada, the United Kingdom and Australia. The Company provides IME services through its medical panel of credentialed physicians and other medical providers. Its clients include property and casualty insurance carriers, law firms, third-party claim administrators and government agencies that use independent services to confirm the veracity of claims by sick or injured individuals and to facilitate care for workers' compensation, automotive, personal injury liability and disability insurance coverage. The Company also provides a range of services, including Medicare compliance services, bill review services and case management services.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Ambulance & Emergency Services
- Sub-Industry: Health Care Services
- Symbol: NYSE:EXAM
- CUSIP: 30066A10
- Web: investorrelations.examworks....
- 50 Day Moving Avg: $35.06
- 200 Day Moving Avg: $35.06
- 52 Week Range: $26.71 - $36.82
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 44.38
- P/E Growth: 0.00
- Net Margins: 1.44%
- Return on Equity: 3.60%
- Return on Assets: 1.21%
Frequently Asked Questions for Examworks Group (NYSE:EXAM)
What is Examworks Group's stock symbol?
Examworks Group trades on the New York Stock Exchange (NYSE) under the ticker symbol "EXAM."
How were Examworks Group's earnings last quarter?
Examworks Group, Inc. (NYSE:EXAM) posted its quarterly earnings data on Tuesday, May, 10th. The company reported $0.08 EPS for the quarter, hitting the Zacks' consensus estimate of $0.08. The firm had revenue of $226.50 million for the quarter, compared to analyst estimates of $217.47 million. Examworks Group had a return on equity of 3.60% and a net margin of 1.44%. The company's revenue was up 15.4% on a year-over-year basis. During the same quarter last year, the company earned $0.05 EPS. View Examworks Group's Earnings History.
Who are some of Examworks Group's key competitors?
Some companies that are related to Examworks Group include Partnership Assurance Group PLC (PA), Novartis AG (NVS), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), HCA Healthcare (HCA), Hospira (HSP), Smith & Nephew plc (SN), Kite Pharma (KITE), Omnicare (OCR), Exelixis (EXEL), VCA (WOOF), NMC Health PLC (NMC), Catalent (CTLT), Valeant Pharmaceuticals Intl (VRX), Health Net (HNT), Patheon NV (PTHN) and Mediclinic International PLC (MDC).
How do I buy Examworks Group stock?
Shares of Examworks Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Examworks Group's stock price today?
MarketBeat Community Rating for Examworks Group (NYSE EXAM)MarketBeat's community ratings are surveys of what our community members think about Examworks Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Examworks Group stock can currently be purchased for approximately $35.06.
Consensus Ratings for Examworks Group (NYSE:EXAM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Examworks Group (NYSE:EXAM)
Analysts' Ratings History for Examworks Group (NYSE:EXAM)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/19/2016||Needham & Company LLC||Reiterated Rating||Hold||N/A|
|6/2/2016||William Blair||Downgrade||Outperform -> Market Perform||N/A|
|2/24/2016||Deutsche Bank AG||Reiterated Rating||Buy||$47.00 -> $45.00||N/A|
|2/4/2016||Goldman Sachs Group, Inc. (The)||Boost Price Target||$26.00 -> $28.00||N/A|
Earnings History for Examworks Group (NYSE:EXAM)Earnings History by Quarter for Examworks Group (NYSE EXAM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2016||Q1||$0.08||$0.08||$217.47 million||$226.50 million||View||N/A|
|2/23/2016||Q4||$0.05||$0.10||$199.06 million||$208.50 million||View||Listen|
|11/4/2015||Q3||$0.09||$0.17||$204.53 million||$206.00 million||View||Listen|
|7/28/2015||Q2||($0.10)||($0.19)||$201.70 million||$208.70 million||View||Listen|
|5/5/2015||Q115||$0.05||$0.05||$192.50 million||$196.32 million||View||Listen|
|11/4/2014||Q314||$0.06||$0.08||$195.80 million||$204.10 million||View||Listen|
|7/29/2014||Q214||$0.04||$0.09||$184.52 million||$196.45 million||View||Listen|
|5/6/2014||Q114||($0.04)||($0.01)||$166.64 million||$173.00 million||View||Listen|
|2/25/2014||Q413||($0.06)||($0.04)||$151.51 million||$158.80 million||View||Listen|
|7/30/2013||Q2 2013||($0.10)||($0.08)||$151.60 million||$156.10 million||View||Listen|
|5/8/2013||Q1 2013||($0.07)||($0.10)||$145.57 million||$148.70 million||View||Listen|
|2/27/2013||Q4 2012||($0.16)||($0.08)||$135.77 million||$139.64 million||View||Listen|
|11/5/2012||Q312||($0.18)||($0.14)||$127.09 million||$130.10 million||View||N/A|
Earnings Estimates for Examworks Group (NYSE:EXAM)
Current Year EPS Consensus Estimate: $0.60 EPS
Next Year EPS Consensus Estimate: $0.79 EPS
Dividend History for Examworks Group (NYSE:EXAM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Examworks Group (NYSE:EXAM)Insider Trades by Quarter for Examworks Group (NYSE:EXAM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/6/2016||De Castro Jose Migue Fernandez||CFO||Sell||9,798||$34.80||$340,970.40|| |
|6/3/2016||Crystal B Patmore||EVP||Sell||2,030||$34.80||$70,644.00|| |
|6/3/2016||James K Price||CEO||Sell||3,853||$34.81||$134,122.93|| |
|6/3/2016||Kevin J Kozlowski||Insider||Sell||2,435||$34.80||$84,738.00|| |
|6/3/2016||Richard E Perlman||Chairman||Sell||3,160||$34.81||$109,999.60|| |
|6/3/2016||Wesley Campbell||President||Sell||3,247||$34.80||$112,995.60|| |
|3/9/2016||Crystal B Patmore||EVP||Sell||8,507||$28.47||$242,194.29|| |
|3/9/2016||Kevin J Kozlowski||Insider||Sell||5,106||$28.47||$145,367.82|| |
|3/9/2016||Wesley Campbell||President||Sell||6,805||$28.47||$193,738.35|| |
|12/9/2015||J Thomas Presby||Director||Buy||4,000||$26.90||$107,600.00|| |
|9/4/2015||Richard E. Perlman||Chairman||Sell||247,217||$34.16||$8,444,932.72|| |
|9/2/2015||Crystal B. Patmore||EVP||Sell||85,084||$34.87||$2,966,879.08|| |
|9/2/2015||Kevin J. Kozlowski||insider||Sell||70,000||$34.36||$2,405,200.00|| |
|9/1/2015||Clare Arguedas||EVP||Sell||10,222||$35.03||$358,076.66|| |
|9/1/2015||Wesley Campbell||President||Sell||71,010||$35.02||$2,486,770.20|| |
|6/15/2015||William A Shutzer||Director||Sell||16,464||$40.18||$661,523.52|| |
|6/4/2015||J Thomas Presby||Director||Sell||20,000||$39.44||$788,800.00|| |
|6/3/2015||William A Shutzer||Director||Sell||3,100||$40.00||$124,000.00|| |
|6/1/2015||William A Shutzer||Director||Sell||16,900||$41.12||$694,928.00|| |
|5/7/2015||J Thomas Presby||Director||Sell||25,000||$41.56||$1,039,000.00|| |
|3/9/2015||Crystal B Patmore||EVP||Sell||3,295||$39.82||$131,206.90|| |
|3/9/2015||De Castro Jose Migue Fernandez||CFO||Sell||4,948||$39.81||$196,979.88|| |
|3/9/2015||Kevin J Kozlowski||Insider||Sell||3,960||$39.67||$157,093.20|| |
|3/9/2015||Wesley Campbell||President||Sell||5,278||$39.66||$209,325.48|| |
|5/13/2014||Crystal Patmore||EVP||Sell||119,460||$32.30||$3,858,558.00|| |
|5/13/2014||De Castro Jose Migue Fernandez||CFO||Sell||207,440||$32.30||$6,700,312.00|| |
|5/13/2014||James Price||CEO||Sell||814,897||$32.30||$26,321,173.10|| |
|5/13/2014||Kevin Kozlowski||Insider||Sell||126,686||$32.30||$4,091,957.80|| |
|5/13/2014||Richard Perlman||Chairman||Sell||939,025||$32.30||$30,330,507.50|| |
|5/13/2014||Wesley Campbell||President||Sell||121,086||$32.30||$3,911,077.80|| |
|5/13/2014||William Shutzer||Director||Sell||474,567||$32.30||$15,328,514.10|| |
|8/2/2013||Clare Arguedas||EVP||Sell||46,027||$24.02||$1,105,568.54|| |
|8/2/2013||Kevin J Kozlowski||Insider||Sell||60,000||$23.69||$1,421,400.00|| |
|8/2/2013||Wesley Campbell||President||Sell||65,000||$23.87||$1,551,550.00|| |
|6/3/2013||De Castro Jose Migue Fernandez||CFO||Buy||2,500||$18.85||$47,125.00|| |
|6/3/2013||James K Price||CEO||Buy||11,000||$18.92||$208,120.00|| |
|5/13/2013||Wesley Campbell||President||Sell||50,000||$18.25||$912,500.00|| |
|3/4/2013||Richard E Perlman||Chairman||Buy||14,500||$14.30||$207,350.00|| |
|3/1/2013||James K Price||CEO||Buy||14,500||$13.97||$202,565.00|| |
|11/14/2012||De Castro Jose Migue Fernandez||CFO||Buy||5,000||$11.48||$57,400.00|| |
|11/14/2012||James K Price||CEO||Buy||18,000||$11.51||$207,180.00|| |
Headline Trends for Examworks Group (NYSE:EXAM)
Latest Headlines for Examworks Group (NYSE:EXAM)
Loading headlines, please wait.
Examworks Group (EXAM) Chart for Sunday, October, 22, 2017